Keefe, Bruyette & Woods upgrades CME Group to Outperform, citing undervaluation despite ongoing litigation over perpetual futures contracts. The firm maintains its $305 price target, suggesting 21% upside from current levels. Analyst Chris Allen notes the recent price drop stems from overstated fears about perpetual futures, which he argues pose minimal risk to CME’s core business.
CME Group’s stock has declined 8% year-to-date and 17% monthly, driven by regulatory scrutiny around its perpetual futures offerings. CEO Terry Duffy confirmed plans to sue the Commodity Futures Trading Commission (CFTC) over the approval of these contracts, emphasizing the firm’s commitment to legal compliance.
Despite the volatility, consensus among Wall Street analysts remains bullish. Of 17 analysts covering CME Group, eight recommend buying or strongly buying the stock. Analysts highlight CME’s low retail exposure in perpetual futures and its strong position in equities index licensing as key differentiators that mitigate systemic risks.
Also Read
- Essential Factors to Evaluate Before Purchasing Your First ETF
- Russian-Flagged Tanker Forwarder Enters the Channel After Departing Primorsk
- The Profit Mindset Shift: The $14.5 trillion growth market hidden in plain sight – HousingWire
- U.S. Initiates Troop Withdrawal from Europe, Defense Secretary Hegseth Criticizes NATO Allies’ Contributions
